PATENT CLAIM ANALYSIS

Application Number: 16063170
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "210180"]

Abstract:
Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.

Claim (Index 46):
The method of  claim 36 , wherein the MEK inhibitor is RO5126766.

Metadata:
- Claim Count in Document: 131.0
- Percentile: 94.0
- Lexical Diversity: 1.63158
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11581865', '15350801', '15683630', '13893141', '13461098']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7673805971582518
- 35 USC 102 Novelty (BERT): 0.5379969263370276
- Combined Prediction Score: 0.7444422300761294
- Mean Citation Score: 309.54825199999993
- Max Citation Score: 333.0288
- Similarity Product: 200.95610592298507

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test